An 18-year-old female presents with extensive eczema and hair loss; what is the appropriate evaluation and management?

Evaluation and Management of Eczema with Hair Loss in an 18-Year-Old Female

Start with optimized topical therapy for the eczema using topical corticosteroids or topical calcineurin inhibitors, while simultaneously evaluating the hair loss pattern to distinguish between alopecia areata, telogen effluvium, or androgenetic alopecia—each requiring different management strategies.

Initial Assessment

For the Eczema

Look specifically for:

• Distribution pattern (flexural creases, trunk, extremities suggest atopic dermatitis)
• Lichenification indicating chronic scratching
• Signs of secondary infection (crusting, weeping, pustules)
• Severity assessment using validated scales

For the Hair Loss

Examine for:

• Pattern: Diffuse thinning (suggests telogen effluvium or androgenetic alopecia) versus discrete patches (suggests alopecia areata)
• Exclamation mark hairs at patch margins (pathognomonic for alopecia areata) 1
• Dermoscopy findings: Yellow dots indicate active alopecia areata progression 1
• Pull test: Easily extracted hairs suggest active telogen effluvium or alopecia areata
• Scalp inflammation or scarring (rule out tinea capitis, scarring alopecia)

Key History Points

• Timing: Did eczema precede hair loss or vice versa?
• Triggers: Recent illness, stress, medications, dietary changes
• Signs of androgen excess: Acne, hirsutism, menstrual irregularities (suggests FPHL/PCOS) 2
• Family history of autoimmune disease or hair loss
• Cosmetic practices (rule out trichotillomania)

Eczema Management

Begin aggressive topical therapy immediately 3:

First-Line Treatment

• Mid-to-high potency topical corticosteroids for active flares (e.g., mometasone cream twice daily)
• Topical calcineurin inhibitors (tacrolimus 0.03-0.1% or pimecrolimus) for maintenance and face/intertriginous areas 3, 4
• Roflumilast cream 0.15% once daily is FDA-approved for mild-to-moderate atopic dermatitis in patients ≥6 years and shows moderate improvement with minimal adverse effects 3

Adjunctive Measures

• Barrier-repair moisturizers applied liberally and frequently
• Wet-wrap therapy for severe flares
• Oral antihistamines for pruritus control
• Consider phototherapy (UVB 311nm or UVA1) if topical therapy inadequate 4

When to Escalate

If topical therapy fails after optimization, consider:

• Alternative diagnoses (contact dermatitis, cutaneous lymphoma)
• Systemic immunosuppressants for severe refractory disease 3

Hair Loss Management

If Alopecia Areata (Patchy Loss with Exclamation Mark Hairs)

For limited patchy disease (<50% scalp involvement):

• Intralesional corticosteroids (triamcinolone acetonide 5-10 mg/mL) are first-line with 62% achieving regrowth 1
• Inject 0.05-0.1 mL per site, producing 0.5 cm diameter hair growth
• Repeat monthly; response typically seen within 12 weeks
• Topical minoxidil 5% can be added as adjunctive therapy 5

For severe disease (≥50% scalp involvement):

• Oral JAK inhibitors (baricitinib, ritlecitinib, deuruxolitinib) are FDA-approved and have transformed management 5
• Contact immunotherapy (DPCP) is an alternative but requires specialized centers 1

Important caveat: Spontaneous remission occurs in 80% with limited patches within 1 year, but only 34-50% in referral populations 1. Extensive disease (>50% loss) has poor prognosis with <10% full recovery 1.

If Telogen Effluvium (Diffuse Thinning, Positive Pull Test)

• Identify and address triggers (stress, illness, nutritional deficiency, medications)
• Reassurance: Self-limited condition with regrowth expected in 3-6 months
• Topical minoxidil 5% may accelerate recovery
• Do not routinely test iron levels unless other clinical indicators present—studies show no consistent association with alopecia areata 1

If Female Pattern Hair Loss (Frontal/Crown Thinning, Retained Hairline)

• Screen for hyperandrogenism: Check free testosterone, DHEA-S, prolactin if signs of androgen excess present 2
• Screen for metabolic syndrome and cardiovascular risk factors 2
• Topical minoxidil 5% twice daily is first-line and FDA-approved 2
• Anti-androgens (spironolactone, finasteride) are second-line if hyperandrogenism confirmed 2

Critical Pitfalls to Avoid

1. Don't assume the eczema and hair loss are unrelated—severe atopic dermatitis can trigger telogen effluvium through systemic inflammation and stress 6

2. Don't delay treatment waiting for spontaneous resolution—while alopecia areata may remit spontaneously, the psychological impact at age 18 is profound and warrants active intervention 1

3. Don't use hazardous systemic treatments for alopecia areata without clear indication—the disease has no direct health impact beyond psychological effects 1

4. Don't miss diffuse alopecia areata—it can mimic telogen effluvium but requires different treatment; dermoscopy helps distinguish 1

5. Don't forget the psychological burden—both conditions significantly impact quality of life in adolescents; offer psychosocial support and consider referral to patient support groups 1, 7

Practical Algorithm

1. Confirm eczema diagnosis → Start topical corticosteroids + calcineurin inhibitors + aggressive moisturization 3
2. Determine hair loss pattern → Dermoscopy + pull test + scalp examination
3. If patchy with exclamation marks → Intralesional steroids + topical minoxidil 1
4. If diffuse thinning → Evaluate for telogen effluvium triggers vs. androgenetic pattern 8, 2
5. If severe alopecia areata (≥50%) → Consider JAK inhibitors 5
6. Monitor response at 3 months → Adjust therapy based on improvement

The combination of severe eczema and hair loss in an 18-year-old female requires simultaneous aggressive management of both conditions while recognizing their potential interconnection through inflammatory pathways 6.